港股異動 | 中生製藥漲近3% 治療新冠肺炎藥的臨牀研究已完成備案登記
格隆匯2月27日丨中生製藥(1177.HK)現報11.36港元,漲2.9%,暫成交1.6億港元,最新總市值1430億港元。中生製藥昨日發公告稱,甘草酸二銨腸溶膠囊聯用維生素C片在治療新型冠狀病毒肺炎的有效性和安全性的臨牀研究,已完成臨牀試驗註冊備案登記。公告表示,集團一直致力於甘草酸類化合物的研究,在該研究領域,獲得多項國內專利授權,並榮獲國家專利金獎及國家重大新藥創制科技重大專項支持。麥格理近日發研報指,截至目前,中港醫藥股受疫情影響的股價調整非常輕微,有部分企業表現仍然出色,繼續實現結構性增長,相信醫藥股將持續受惠,首選中生製藥,予目標價13.68港元及“跑贏大市”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.